Published October 29, 2015 | Version v1
Journal article Open

Quality of Life after Post-Prostatectomy Intensity Modulated Radiation Therapy: Pelvic Nodal Irradiation Is Not Associated with Worse Bladder, Bowel, or Sexual Outcomes

  • 1. University of Chicago

Description

Background: Limited data exist regarding toxicity and quality of life (QOL) after post-prostatectomy intensity modulated radiation therapy (IMRT) and whether pelvic nodal RT influences these outcomes.

Methods: 118 men were treated with curative-intent RT after radical prostatectomy. 69 men (58%) received pelvic nodal RT. QOL data and physician-assigned toxicity were prospectively collected. Changes in QOL from baseline were assessed with Wilcoxon signed-rank tests and risk factors associated with each domain were identified with generalized estimating equation (GEE) models. Late freedom from (FF) toxicity was estimated by the Kaplan-Meier method and comparisons were tested using the log-rank test.

Results: Urinary irritation/obstruction, bowel, and sexual domain scores declined at 2 months (all P ≤ 0.01) but were no different than baseline at subsequent visits through 4 years of follow-up. At 4 years, FF grade 2+ GI toxicity was 90% and FF grade 2+ GU toxicity was 89%. On GEE analysis, pelvic nodal RT was associated with decreased bowel function (P = 0.09) and sexual function (P = 0.01). On multivariate analysis, however, there was no significant association with either decreased bowel (P = 0.31) or sexual (P = 0.84) function. There was also no association with either FF grade 2+ GI toxicity (P = 0.24) or grade 2+ GU toxicity (P = 0.51).

Conclusions: Receipt of pelvic nodal RT was not associated with inferior QOL or toxicity compared to prostate bed alone RT. For the entire cohort, RT was associated with only temporary declines in patient-reported urinary, bowel, or sexual QOL.

Data availability

To ensure compliance with the existing IRB approval letter and HIPAA compliance for patients, the full deidentified dataset cannot be made available without prior written approval from the University of Chicago Hospital IRB. Requests for deidentified data can be made to Dr. Christopher Daugherty, Chairman of the University of Chicago Hospital IRB at cdaugher@medicine.bsd.uchicago.edu.

Files

journal.pone.0141639.pdf

Files (405.0 kB)

Name Size Download all
Article
md5:bf350ee06a6ec632841b024afa3afb52
405.0 kB Preview Download

Additional details

Identifiers

DOI
10.1371/journal.pone.0141639
Other
oai:uchicago.tind.io:7493

UChicago Information

Division(s)
Biological Sciences Division
Department(s)
Public Health Sciences, Radiation and Cellular Oncology